Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Trurapi 100 units/ml solution for injection in pre-filled pen

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Insulin aspart may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Insulin aspart

Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for

Trurapi is used to reduce the high blood sugar level in adults, adolescents and children aged 1 year and above with diabetes mellitus (diabetes). Diabetes is a disease where your body does not produce enough insulin to control the level of your blood sugar. Treatment with insulin aspart helps to prevent complications from your diabetes. Insulin aspart will start to lower your blood sugar 10-20 minutes after you inject it, a maximum effect occurs between 1 and 3 hours after the injection and the effect lasts for 3-5 hours. Due to this short action insulin aspart should normally be taken in combination with intermediate‐acting or long‐acting insulin preparations.

What you need to know before you take it

e Trurapi Do not use Trurapi

  • If you are allergic to insulin aspart, or any of the other ingredients of this medicine (listed in section 6).
  • If you suspect hypoglycaemia (low blood sugar) is starting (see "Summary of serious and very common side effects" in section 4)
  • If the pre-filled pen is dropped, damaged or crushed.
  • If it has not been stored correctly or been frozen (see "How to store Trurapi" in section 5).
  • If the insulin does not appear clear and colourless. If any of these applies, do not use Trurapi. Talk with your doctor, nurse or pharmacist for advice. Before using Trurapi
  • Check the label to make sure it is the right type of insulin.
  • Always use a new needle for each injection to prevent contamination.
  • Needles and the pre-filled pen must not be shared.
  • Trurapi is only suitable for injecting under the skin. Speak to your doctor if you need to inject your insulin by another method. Warnings and precautions Record the brand name ("Trurapi") and Lot number (included on the outer cartons and labels of each pre-filled pen) of the medicine you are using and provide this information when reporting any side effects.

Some conditions and activities can affect your need for insulin. Consult your doctor:

  • If you have trouble with your kidneys or liver, or with your adrenal, pituitary or thyroid glands.
  • If you exercise more than usual or if you want to change your usual diet, as this may affect your blood sugar level.
  • If you are ill, carry on taking your insulin and consult your doctor.
  • If you are going abroad, travelling over time zones may affect your insulin needs and the timing of your injections. Children and adolescents Do not give this medicine to children below 1 year of age since no clinical trials have been carried out in children below the age of 1 year.

Ask your doctor, nurse or pharmacist for advice before using this medicine while pregnant or breast-feeding. Driving and using machines Please ask your doctor whether you can drive a car or use a machine:

  • If you have frequent hypoglycaemia.
  • If you find it hard to recognise hypoglycaemia. If your blood sugar is low or high, your concentration and ability to react might be affected and therefore also your ability to drive or use a machine. Bear in mind that you could endanger yourself or others.

Your blood sugar level may fall (hypoglycaemia) if you take:

  • Other medicines for the treatment of diabetes
  • Monoamine oxidase inhibitors (MAOI) (used to treat depression)
  • Beta-blockers (used to treat high blood pressure)
  • Angiotensin converting enzyme (ACE) inhibitors (used to treat certain heart conditions or high blood pressure)
  • Salicylates (used to relieve pain and lower fever)
  • Anabolic steroids (such as testosterone)
  • Sulphonamides (used to treat infections).

3. How to use Trurapi

Pioglitazone (tablets used for the treatment of type 2 diabetes) Some patients with long-standing type 2 diabetes and heart disease or previous stroke who were treated with pioglitazone and insulin experienced the development of heart failure. Inform your doctor as soon as possible if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling (oedema). If you have taken any of the medicines listed here, tell your doctor, nurse or pharmacist. Insulin aspart and alcohol If you drink alcohol, your need for insulin may change as your blood sugar level may either rise or fall. Careful monitoring is recommended.

4. Possible side effects

Uncommon (may affect up to 1 in 100 people)

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Signs of allergy: Local allergic reactions (pain, redness, hives, inflammation, bruising, swelling and itching) at the injection site may occur. These usually disappear after a few weeks of using your insulin. If they do not disappear, or if they spread throughout your body, talk to your doctor immediately (see also "Serious allergic reactions" above).

If you stop using your insulin Do not stop using your insulin without speaking with a doctor, who will tell you what needs to be done. This could lead to very high blood sugar (severe hyperglycaemia) and ketoacidosis (see "Effects from diabetes" in section 4).

Trurapi contains sodium This medicine contains less than 1 mmol (23 mg) sodium per dose, that is to say essentially "sodiumfree".

Beta-blockers (used to treat high blood pressure) may weaken or suppress entirely the first warning symptoms which help you to recognise low blood sugar.

Keep this medicine out of the sight and reach of children.

If you have any further questions on the use of this medicine, ask your doctor, nurse or pharmacist.

Skin changes at the injection site: If you inject insulin too often at the same place, the fatty tissue under the skin at the injection site may shrink (lipoatrophy) or thicken (lipohypertrophy) (may affect up to 1 in 100 people). Lumps under the skin may also be caused by build-up of a protein called amyloid (cutaneous amyloidosis; how often this occurs is not known). The insulin may not work very well if you inject into a lumpy area. Change the injection site with each injection to help prevent these skin changes. If you notice your skin pitting or thickening at the injection site, tell your doctor or nurse. These reactions can become more severe, or they may change the absorption of your insulin, if you inject in such a site.

There are no restrictions on treatment with insulin aspart during breast-feeding.

Trurapi has a rapid onset of effect therefore if hypoglycaemia occurs, you may experience it earlier after an injection when compared to soluble human insulin.

Octreotide and lanreotide (used for treatment of acromegaly, a rare hormonal disorder that usually occurs in middle-aged adults, caused by the pituitary gland producing excess growth hormone) may either increase or decrease your blood sugar level.

5. How to store Trurapi

If you use more insulin than you should If you use too much insulin your blood sugar gets too low (hypoglycaemia) (see "Summary of serious and very common side effects" in section 4).

Other medicines and Trurapi Tell your doctor, nurse or pharmacist if you are taking, have recently taken or might take any other medicines. Some medicines affect your blood sugar level and this may mean that your insulin dose has to change. Listed below are the most common medicines which may affect your insulin treatment.

Your blood sugar level may rise (hyperglycaemia) if you take:

  • Oral contraceptives (birth control pills)
  • Thiazides (used to treat high blood pressure or excessive fluid retention)
  • Glucocorticoids (such as 'cortisone' used to treat inflammation)
  • Thyroid hormones (used to treat thyroid gland disorders)
  • Sympathomimetics (such as epinephrine [adrenaline], or salbutamol, terbutaline used to treat asthma)
  • Growth hormone (medicine for stimulation of skeletal and somatic growth and pronounced influence on the body's metabolic processes)
  • Danazol (medicine acting on ovulation).

Other side effects

Pregnancy and breast-feeding If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine. Insulin aspart can be used during pregnancy. Your insulin dose may need to be changed during pregnancy and after delivery. Careful control of your diabetes, particularly prevention of hypoglycaemia, is important for the health of your baby.

Dose and when to use your insulin Always use your insulin and adjust your dose exactly as your doctor has told you. Check with your doctor, nurse or pharmacist if you are not sure. Insulin aspart is generally used immediately before a meal. Eat a meal or snack within 10 minutes of the injection to avoid low blood sugar. When necessary, insulin aspart can be given soon after a meal (see "How and where to inject" below for information). Do not change your insulin unless your doctor tells you to. If your doctor has switched you from one type or brand of insulin to another, your dose may have to be adjusted by your doctor. Use in children and adolescents Insulin aspart can be used in adolescents and children aged 1 year and above instead of soluble human insulin when a rapid onset of effect is preferred. For example, when it is difficult to dose the child in relation to meals. Use in special patient groups If you have reduced kidney or liver function, or if you are above 65 years of age, you need to check your blood sugar more regularly and discuss changes in your insulin dose with your doctor.

How to take it

and where to inject Trurapi is for injection under the skin (subcutaneously). You must never inject yourself directly into a vein (intravenously) or muscle (intramuscularly). Trurapi is only suitable for injecting under the skin. Speak to your doctor if you need to inject your insulin by another method. With each injection, change the injection site within the particular area of skin that you use. This may reduce the risk of developing lumps or skin pitting (see section 4 "Possible side effects"). The best places to give yourself an injection are: the front of your waist (abdomen), the upper arm or the front of your thighs. The insulin will work more quickly if you inject into the front of your waist (abdomen). You should always measure your blood sugar regularly. How to handle Trurapi pre‐filled pen Trurapi is available in a pre-filled disposable pen (called SoloStar) containing insulin aspart. Each SoloStar pen delivers 1-80 units in increments of 1 unit. Read carefully the instructions for use included in this package leaflet. You must use the pen as described in the Instructions for Use.

If you forget to use your insulin If you forget to use your insulin your blood sugar may get too high (hyperglycaemia) (see "Effects from diabetes" in section 4).

Summary of serious and very common side effects Low blood sugar (hypoglycaemia) is a very common side effect. It may affect more than 1 in 10 people. Low blood sugar may occur if you:

  • Inject too much insulin.
  • Eat too little or miss a meal.
  • Exercise more than usual.
  • Drink alcohol (see "Insulin aspart and alcohol" in section 2). Signs of low blood sugar: Cold sweat; cool pale skin; headache; rapid heartbeat; feeling sick; feeling very hungry; temporary changes in vision; drowsiness; unusual tiredness and weakness; nervousness or tremor; feeling anxious; feeling confused; difficulty in concentrating. Severe low blood sugar can lead to unconsciousness. If prolonged severe low blood sugar is not treated, it can cause brain damage (temporary or permanent) and even death. You may recover more quickly from unconsciousness with an injection of the hormone glucagon by someone who knows how to use it. If you are given glucagon you will need glucose or a sugar snack as soon as you are conscious. If you do not respond to glucagon treatment, you will have to be treated in a hospital. What to do if you experience low blood sugar:
  • If you experience low blood sugar, eat glucose tablets or another high sugar snack (e.g. sweets, biscuits, fruit juice). Measure your blood sugar if possible and rest. Always carry glucose tablets or high sugar snacks with you, just in case.
  • When symptoms of low blood sugar have disappeared or when blood sugar level is stabilised, continue insulin treatment as usual.
  • If you have such a low blood sugar that it makes you pass out, if you have had need for injection of glucagon, or if you have experienced many incidents of low blood sugar, talk with a doctor. The amount or timing of insulin, food or exercise may need to be adjusted. Tell relevant people that you have diabetes and what the consequences may be, including the risk of passing out (become unconscious) due to low blood sugar. Let them know that if you pass out, they must turn you on your side and get medical help straight away. They must not give you any food or drink due to risk of suffocation. Serious allergic reactions to Trurapi or one of its ingredients (called a systemic allergic reaction) is a very rare side effect but can potentially be life threatening. It may affect up to 1 in 10,000 people. Seek medical advice immediately:
  • If signs of allergy spread to other parts of your body.
  • If you suddenly feel unwell, and you: start sweating; start being sick (vomiting); have difficulty in breathing; have a rapid heartbeat; feel dizzy. If you notice any of these signs, seek medical advice immediately.

Always ensure you use the correct pen before you inject your insulin.

Legende / Legend SAP-Nr. / Plant PM code: Sprachvariante / Country code: Version: Datum / Date: DMC-Inhalt / DMC content:

954212 028 2 09.02.2026 DR07 <MAT>954212

Abmessungen / Dimensions: Schriftgröße / Font size: Zeilenabstand / Line spacing: Seite / Page:

594 × 420 mm 10 Pt 11 Pt 1/2

Druckbare Farben / Printing colours

Technische Information / Technical information

Black

Kontur / Outline

Vision problems: When you first start your insulin treatment, it may disturb your vision, but the disturbance is usually temporary. Swollen joints: When you start using insulin, water retention may cause swelling around your ankles and other joints. Normally this soon disappears. If not, talk to your doctor. Diabetic retinopathy (an eye disease related to diabetes which can lead to loss of vision): If you have diabetic retinopathy and your blood sugar level improves very fast, the retinopathy may get worse. Ask your doctor about this. Rare (may affect up to 1 in 1,000 people) Painful neuropathy (pain due to nerve damage): If your blood sugar level improves very fast, you may get nerve related pain. This is called acute painful neuropathy and is usually transient. Reporting of side effects If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any

Possible side effects

not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine. Effects from diabetes High blood sugar (hyperglycaemia)

Do not use this medicine after the expiry date which is stated on the label and carton. The expiry date refers to the last day of that month. Before the first use store your Trurapi in a refrigerator (2°C – 8°C). Do not freeze. Keep the pre-filled pen in the outer carton in order to protect from light. Keep your Trurapi pre‐filled pen in use at room temperature (below 30°C) for a maximum of 4 weeks. Do not keep the pre‐filled pen that you are using in the fridge. The pre‐filled pen should not be stored with the needle attached. Always keep the cap on the pre‐filled pen when you are not using it in order to protect from light. Do not use Trurapi pre-filled pen if the solution is coloured or it has solid pieces in it. You must use it only if it looks like water. Check this each time you inject yourself. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

How to store it

and care for your pen

Handling needles

If you see air bubbles

Units of insulin in your pen

If you find it hard to press the button in:

  • Take care when handling needles – this is to prevent needle injury and cross-infection.
  • You may see air bubbles in the insulin. This is normal, they will not harm you.
  • Your pen contains a total of 300 units of insulin. You can select doses from 1 to 80 units in steps of 1 unit. Each pen contains more than one dose.
  • You can see roughly how many units of insulin are left by looking at where the plunger is on the insulin scale.
  • Change the needle (see STEP 6 and STEP 2) then do a safety test (see STEP 3).
  • If you still find it hard to press in, get a new pen.
  • Never use a syringe to remove insulin from your pen.

Legende / Legend SAP-Nr. / Plant PM code: Sprachvariante / Country code: Version: Datum / Date:

954212 028 2 09.02.2026 DR07

Abmessungen / Dimensions: Schriftgröße / Font size: Zeilenabstand / Line spacing: Seite / Page:

594 × 420 mm 10 Pt 11 Pt 2/2

Druckbare Farben / Printing colours

Technische Information / Technical information

Cyan Magenta Yellow Black

Kontur / Outline

  • You can clean the outside of your pen by wiping it with a damp cloth (water only). Do not soak, wash or lubricate your pen – this may damage it.
  • Remove and throw away your used pen as told by your pharmacist or local authority.
  • For further information on the storage and use of your pen please refer to sections 2 and 5 of the package leaflet.

Contents of the pack and other information

What Trurapi contains

  • The active substance is insulin aspart. One ml of the solution contains 100 units (equivalent to 3.5 mg) of insulin aspart. Each pre-filled pen (SoloStar) contains 3 ml of solution for injection, equivalent to 300 units of insulin aspart. Each pre-filled pen (SoloStar) delivers 1 – 80 units in steps of 1 unit.
  • The other ingredients are: phenol, metacresol, zinc chloride, polysorbate 20, sodium chloride, hydrochloric acid/sodium hydroxide and water for injections. Sodium hydroxide or hydrochloric acid may have been used to adjust the acidity (see "Trurapi contains sodium" in section 2). What Trurapi looks like and contents of the pack Trurapi solution for injection is a clear, colourless solution. Each pre-filled pen (SoloStar) contains 3 ml. Only use needles that are compatible for use with Trurapi. Trurapi in pre-filled pen (SoloStar) comes in a pack of 1, 5 or 10 pre-filled pens. Not all pack sizes may be marketed. Marketing Authorisation Holder Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK Tel: 0800 035 2525 Email: [email protected]

High blood sugar may occur if you:

  • Have not injected enough insulin.
  • Forget to inject your insulin or stop using insulin.
  • Repeatedly inject less insulin than you need.
  • Get an infection and/or a fever.
  • Eat more than usual.
  • Exercise less than usual.

Manufacturer Sanofi-Aventis Deutschland GmbH, D-65926 Frankfurt am Main, Germany.

Warning signs of high blood sugar: The warning signs appear gradually. They include: increased urination; feeling thirsty; losing your appetite; feeling sick (nausea or vomiting); feeling drowsy or tired; flushed; dry skin; dry mouth and a fruity (acetone) smell of the breath.

This leaflet was last revised in February 2026

What to do if you experience high blood sugar

  • If you get any of the above signs: test your blood sugar level, test your urine for ketones if you can, then seek medical advice immediately.
  • These may be signs of a very serious condition called diabetic ketoacidosis (buildup of acid in the blood because the body is breaking down fat instead of sugar). If you do not treat it, this could lead to diabetic coma and eventually death.

This leaflet does not contain all the information about your medicine. If you have any questions or are not sure about anything, ask your doctor or pharmacist

<MAT>954212

Trurapi is a modern insulin (insulin analogue) with a rapid-acting effect. Modern insulin products are improved versions of human insulin.

Skin changes at the injection site The injection site should be rotated to prevent skin changes such as lumps under the skin. The insulin may not work very well if you inject into a lumpy area (see "How to use Trurapi"). Contact your doctor if you are currently injecting into a lumpy area before you start injecting in a different area. Your doctor may tell you to check your blood sugar more closely, and to adjust your insulin or your other antidiabetic medications dose.

Trurapi solution for injection in pre-filled pen (SoloStar) INSTRUCTIONS FOR USE Important information

✗ Never share your pen – it is only for you. ✗ Never use your pen if it is damaged or if you are not sure that it is working

✓ Take a new pen out of the fridge at least 1 hour

✓ Always use a new sterile needle for each injection.

✓ Always do a safety test before each injection – this is

✗

✓

✓ ✓

Rubber seal Insulin scale

to: check your pen and the needle are working properly. make sure that you get the correct insulin dose.

Select 2 units by turning the dose selector until the dose pointer is at the 2 mark.

Never select a dose or press the injection button without a needle attached. This may damage your pen.

Make sure a needle is attached and the dose is set to '0'.

STEP 5: Inject your dose

✗

If you find it hard to press the injection button in, do not force it as this may break your pen. See the section below for help.

Choose a place to inject as shown in the picture

220

260

140

180

20

60

100

220

260

100

140

180

20

60

Stomach

60

100

140

180

Turn the dose selector until the dose pointer lines up with your dose.

  • If you turn past your dose, you can turn back down.
  • If there are not enough units left in your pen for your dose, the dose selector will stop at the number of units left.
  • If you cannot select your full prescribed dose, use a new pen or inject the remaining units and use a new pen to complete your dose.

Press the injection button all the way in.

  • When insulin comes out of the needle tip, your pen is working correctly.

Push the needle into your skin as shown by your doctor, pharmacist or nurse.

  • Do not touch the injection button yet.

20 60 100 140 180 220

02

06

001

041

20 60

081

260

022

220

062

✓ Take care when handling needles – this is to prevent ✗

needle injury and cross-infection. Never put the inner needle cap back on.

Put the outer needle cap back on the needle, and use it to unscrew the needle from the pen.

  • To reduce the risk of accidental needle injury, never replace the inner needle cap.
  • If your injection is given by another person, or if you are giving an injection to another person, special caution must be taken by this person when removing and disposing of the needle.
  • Follow recommended safety measures for removal and disposal of needles (contact your doctor, pharmacist or nurse) in order to reduce the risk of accidental needle injury and transmission of infectious diseases. Throw away the used needle in a puncture resistant container, or as told by your pharmacist or local authority.

260

100

140

180

20

60

Place your thumb on the injection button. Then press all the way in and hold.

  • Do not press at an angle – your thumb could block the dose selector from turning.

260

180

220

100

140

20

60

Pull off the outer needle cap. Keep this for later.

Buttocks

Thighs

20

20

60

100

140

180

220

260

20

60

100

140

180

220

260

220

260

Keep the needle straight and screw it onto the pen until fixed. Do not overtighten.

Check that the insulin is clear.

  • Do not use the pen if the insulin looks cloudy, coloured or contains particles.

Injection button

Plunger*

STEP 6: Remove the needle

Upper arms

Pull off the pen cap.

260

STEP 4: Select the dose

Take a new needle and peel off the protective seal.

Dose pointer

  • You will not see the plunger until you have injected a few doses.

STEP 3: Do a safety test

Check the name and expiry date on the label of your pen.

  • Make sure you have the correct insulin. This is especially important if you have other injector pens.
  • Never use your pen after the expiry date.

Dose window

Dose selector Pen cap

STEP 2: Attach a new needle This helps stop blocked needles, contamination and infection. Only use needles that are compatible for use with Trurapi

Insulin name

Cartridge holder

180

  • a new sterile needle (see STEP 2).
  • a puncture resistant container for used needles and pens (see Throwing your pen away).

220

If you have any questions about your pen or about diabetes, ask your doctor, pharmacist or nurse or call the Sanofi number on the front of this leaflet.

100

  • Talk with your doctor, pharmacist or nurse about how to inject, before using your pen.
  • Ask for help if you have problems handling the pen, for example if you have problems with your sight.
  • Read all package leaflet information and instructions before using your pen. If you do not follow all of these instructions, you may get too much or too little insulin.

STEP 1: Check your pen before you inject. Cold insulin is more painful to inject.

Get to know your pen

140

Extra items you will need:

20

properly. ✓ Always perform a safety test. ✓ Always carry a spare pen and spare needles in case they get lost or stop working. ✗ Never re-use needles. If you do you might not get your dose (underdosing) or get too much (overdosing) as the needle could block.

Need help?

60

Read this first

Learn to inject

How to read the dose window Even numbers are shown in line with the dose pointer:

Put the pen cap back on.

  • Do not put the pen back in the fridge.

20

60

100

140

180

220

260

100 260

180

220

140 20

60

100

140

260

180

220

100

140

20

60

180 02

06

001

041

081

022

260

062

If no insulin appears:

  • You may need to repeat this step up to 3 times before seeing insulin.
  • If no insulin comes out after the third time, the needle may be blocked. If this happens:
  • change the needle (see STEP 6 and STEP 2),
  • then repeat the safety test (STEP 3).
  • Do not use your pen if there is still no insulin coming out of the needle tip. Use a new pen.
  • Never use a syringe to remove insulin from your pen. 220

Pull off the inner needle cap and throw away.

20 units selected Odd numbers are shown as a line between even numbers:

Keep the injection button held in and when you see "0" in the dose window, slowly count to 10.

  • This will make sure you get your full dose.

21 units selected

10 secs

180

220

260

20

60

100

140

After holding and slowly counting to 10, release the injection button. Then remove the needle from your skin.

Frequently asked questions about Trurapi 100 units/ml solution for injection in pre-filled pen

How do I take Trurapi 100 units/ml solution for injection in pre-filled pen?

Trurapi 100 units/ml solution for injection in pre-filled pen comes as injection containing 100iu. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Trurapi 100 units/ml solution for injection in pre-filled pen?

The active substance in Trurapi 100 units/ml solution for injection in pre-filled pen is insulin aspart.

Are there equivalent medicines to Trurapi 100 units/ml solution for injection in pre-filled pen?

Medicines with the same active substance, strength and form include: Fiasp 100 units/mL Penfill solution for injection in cartridge, Fiasp 100 units/mL solution for injection in vial, Trurapi 100 units/ml solution for injection in cartridge. In total there are 4 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Trurapi 100 units/ml solution for injection in pre-filled pen, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Trurapi 100 units/ml solution for injection in pre-filled pen without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Insulin aspart (12 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Trurapi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

4.2. Posology and method of administration

Posology

The potency of insulin analogues, including insulin aspart, is expressed in units, whereas the potency of human insulin is expressed in international units.

Trurapi dosing is individual and determined in accordance with the needs of the patient. It should normally be used in combination with intermediate-acting or long-acting insulin.

Blood glucose monitoring and insulin dose adjustments are recommended to achieve optimal glycaemic control.

The individual insulin requirement in adults and children is usually between 0.5 and 1.0 unit/kg/day. In a basal-bolus treatment regimen 50-70% of this requirement may be provided by Trurapi and the remainder by intermediate-acting or long-acting insulin.

Adjustment of dose may be necessary if patients undertake increased physical activity, change their usual diet or during concomitant illness.

Transfer from other insulin medicinal products

When transferring from other insulin medicinal products, adjustment of the Trurapi dose and the dose of the basal insulin may be necessary. Trurapi has a faster onset and a shorter duration of action than soluble human insulin. When injected subcutaneously into the abdominal wall, the onset of action will occur within 10 - 20 minutes of injection. The maximum effect is exerted between 1 and 3 hours after the injection. The duration of action is 3 - 5 hours.

Close glucose monitoring is recommended during the transfer and in the initial weeks thereafter (see section 4.4).

Special populations

Elderly (≥ 65 years old)

Trurapi can be used in elderly patients.

In elderly patients, glucose monitoring should be intensified and the insulin aspart dose adjusted on an individual basis.

Renal impairment

Renal impairment may reduce the patient's insulin requirements.

In patients with renal impairment, glucose monitoring should be intensified and the insulin aspart dose adjusted on an individual basis.

Hepatic impairment

Hepatic impairment may reduce the patient's insulin requirements.

In patients with hepatic impairment, glucose monitoring should be intensified and the insulin aspart dose adjusted on an individual basis.

Paediatric population

Trurapi can be used in adolescents and children aged 1 year and above in preference to soluble human insulin when a rapid onset of action might be beneficial, for example, in the timing of the injections in relation to meals (see sections 5.1 and 5.2).

The safety and efficacy of Trurapi in children below 1 year of age have not been established.

No data are available.

Method of administration

Insulin aspart is a rapid-acting insulin analogue.

Trurapi is administered subcutaneously by injection in the upper arms, thighs, buttocks or abdomen. Injection sites should always be rotated within the same region in order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see section 4.4 and 4.8). Subcutaneous injection in the abdominal wall ensures a faster absorption than other injection sites. Compared to soluble human insulin the faster onset of action of insulin aspart is maintained regardless of the injection site. The duration of action will vary according to the dose, injection site, blood flow, temperature and level of physical activity.

Due to the faster onset of action, insulin aspart should generally be given immediately before a meal. When necessary insulin aspart can be given soon after a meal.

Trurapi 100 units/ml in pre-filled pen is only suitable for subcutaneous injections. If administration by syringe, intravenous injection or infusion pump is necessary, a vial should be used. Other insulin aspart medicinal products offering such an option should be used. Trurapi in pre‑filled pen delivers 1-80 units in increments of 1 unit.

Patients must visually verify the dialled units on the dose counter of the pen. Therefore, the requirement for patients to self-inject is that they can read the dose counter on the pen. Patients who are blind or have poor vision must be instructed to always get help/assistance from another person who has good vision and is trained in using the insulin device.

For detailed user instructions, please refer to the package leaflet.

4.3. Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4. Special warnings and precautions for use

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered medicinal product should be clearly recorded.

Injection technique

Patients must be instructed to perform continuous rotation of the injection site to reduce the risk of developing lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin absorption and worsened glycaemic control following insulin injections at sites with these reactions. A sudden change in the injection site to an unaffected area has been reported to result in hypoglycaemia. Blood glucose monitoring is recommended after the change in the injection site, and dose adjustment of antidiabetic medicinal products may be considered.

Hyperglycaemia

Inadequate dosing or discontinuation of treatment, especially in type 1 diabetes, may lead to hyperglycaemia and diabetic ketoacidosis. Usually the first symptoms of hyperglycaemia develop gradually over a period of hours or days. They include thirst, increased frequency of urination, nausea, vomiting, drowsiness, flushed dry skin, dry mouth, loss of appetite as well as acetone odour of breath. In type 1 diabetes, untreated hyperglycaemic events eventually lead to diabetic ketoacidosis, which is potentially lethal.

Hypoglycaemia

Omission of a meal or unplanned, strenuous physical exercise may lead to hypoglycaemia.

Especially in children, care should be taken to match insulin doses (especially in basal-bolus regimens) with food intake, physical activities and current blood glucose level in order to minimise the risk of hypoglycaemia.

Hypoglycaemia may occur if the insulin dose is too high in relation to the insulin requirement. In case of hypoglycaemia or if hypoglycaemia is suspected insulin aspart must not be injected. After stabilisation of patient's blood glucose adjustment of the dose should be considered (see sections 4.8 and 4.9).

Patients whose blood glucose control is greatly improved, e.g. by intensified insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia, and should be advised accordingly. Usual warning symptoms may disappear in patients with longstanding diabetes.

A consequence of the pharmacodynamics of rapid‑acting insulin analogues is that if hypoglycaemia occurs, it may occur earlier after an injection when compared with soluble human insulin.

Since insulin aspart should be administered in immediate relation to a meal, the rapid onset of action should be considered in patients with concomitant diseases or treatment where a delayed absorption of food might be expected.

Concomitant illness, especially infections and feverish conditions, usually increases the patient's insulin requirements. Concomitant diseases in the kidney, liver or affecting the adrenal, pituitary or thyroid gland can require changes in the insulin dose.

When patients are transferred between different types of insulin medicinal products, the early warning symptoms of hypoglycaemia may change or become less pronounced than those experienced with their previous insulin.

Transfer from other insulin medicinal products

Transferring a patient to another type or brand of insulin should be done under strict medical supervision. Changes in strength, brand (manufacturer), type, origin (animal, human insulin or human insulin analogue) and/or method of manufacture (recombinant DNA versus animal source insulin) may result in the need for a change in dose. Patients transferred to Trurapi from another type of insulin may require an increased number of daily injections or a change in dose from that used with their usual insulin medicinal products. If an adjustment is needed, it may occur with the first dose or during the first few weeks or months.

Injection site reactions

As with any insulin therapy, injection site reactions may occur and include pain, redness, hives, inflammation, bruising, swelling and itching. Continuous rotation of the injection site within a given area reduces the risk of developing these reactions. Reactions usually resolve in a few days to a few weeks. On rare occasions, injection site reactions may require discontinuation of insulin aspart.

Combination of insulin aspart with pioglitazone

Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. This should be kept in mind if treatment with the combination of pioglitazone and insulin aspart is considered. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema. Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs.

Avoidance of accidental mix-ups/medication errors

Patients must be instructed to always check the insulin label before each injection to avoid accidental mix-ups between Trurapi and other insulin medicinal products.

Insulin antibodies

Insulin administration may cause insulin antibodies to form. In rare cases, the presence of such insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency to hyper- or hypoglycaemia.

Travel

Before travelling between different time zones, the patient should seek the doctor's advice since this may mean that the patient has to take the insulin and meals at different times.

Sodium

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to sayessentially “sodium‑free”.

4.5. Interaction with other medicinal products and other forms of interaction

A number of medicinal products are known to interact with the glucose metabolism.

The following substances may reduce the patient's insulin requirements:

Oral antidiabetic medicinal products, monoamine oxidase inhibitors (MAOI), beta-blockers, angiotensin converting enzyme (ACE) inhibitors, salicylates, anabolic steroids and sulphonamides.

The following substances may increase the patient's insulin requirements:

Oral contraceptives, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth hormone and danazol.

Beta-blockers may mask the symptoms of hypoglycaemia.

Octreotide/lanreotide may either increase or decrease the insulin requirement.

Alcohol may intensify or reduce the hypoglycaemic effect of insulin.

4.6. Fertility, pregnancy and lactation

Pregnancy

Trurapi (insulin aspart) can be used in pregnancy. Data from two randomised controlled clinical trials (322 and 27 exposed pregnancies) do not indicate any adverse reaction of insulin aspart on pregnancy or on the health of the fetus/newborn when compared to human insulin (see section 5.1).

Intensified blood glucose control and monitoring of pregnant women with diabetes (type 1 diabetes, type 2 diabetes or gestational diabetes) are recommended throughout pregnancy and when contemplating pregnancy. Insulin requirements usually fall in the first trimester and increase subsequently during the second and third trimester. After delivery, insulin requirements normally return rapidly to pre-pregnancy values.

Breast-feeding

There are no restrictions on treatment with Trurapi during breast-feeding. Insulin treatment of the breast-feeding mother presents no risk to the baby. However, the Trurapi dose may need to be adjusted.

Fertility

Animal reproduction studies have not revealed any differences between insulin aspart and human insulin regarding fertility (see section 5.3).

4.7. Effects on ability to drive and use machines

The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or using machines).

Patients should be advised to take precautions to avoid hypoglycaemia while driving, this is particularly important in those who have reduced or absent awareness of the warning signs of hypoglycaemia or have frequent episodes of hypoglycaemia. The advisability of driving should be considered in these circumstances.

4.8. Undesirable effects

Summary of the safety profile

Adverse reactions observed in patients using insulin aspart are mainly due to the pharmacologic effect of insulin.

The most frequently reported adverse reaction during treatment is hypoglycaemia. The frequencies of hypoglycaemia vary with patient population, dose regimens and level of glycaemic control (see section 4.8 Description of selected adverse reactions).

At the beginning of the insulin treatment, refraction anomalies, oedema and injection site reactions (pain, redness, hives, inflammation, bruising, swelling and itching at the injection site) may occur. These reactions are usually of transitory nature. Fast improvement in blood glucose control may be associated with acute painful neuropathy, which is usually reversible. Intensification of insulin therapy with abrupt improvement in glycaemic control may be associated with temporary worsening of diabetic retinopathy, while long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy.

Tabulated list of adverse reactions

Adverse reactions listed below are based on clinical trial data and classified according to System Organ Class. Frequency categories are defined according to the following convention: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).

MedDRA system organ classes

Very common

Uncommon

Rare

Very rare

Not known

Immune system disorders

Urticaria, rash, eruptions

Anaphylactic reactions*

Metabolism and nutrition disorders

Hypoglycaemia*

Nervous system disorders

Peripheral neuropathy (painful neuropathy)

Eye disorders

Refraction disorders, diabetic retinopathy

Skin and subcutaneous tissue disorders

Lipodystrophy*

Cutaneous amyloidosis*

General disorders and administration site conditions

Injection site reactions, oedema

*See section 4.8 Description of selected adverse reactions

Description of selected adverse reactions

Anaphylactic reactions

The occurrence of generalised hypersensitivity reactions (including generalised skin rash, itching, sweating, gastrointestinal upset, angioneurotic oedema, difficulties in breathing, palpitation and reduction in blood pressure) is very rare but can potentially be life threatening.

Hypoglycaemia

The most frequently reported adverse reaction is hypoglycaemia. It may occur if the insulin dose is too high in relation to the insulin requirement. Severe hypoglycaemia may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or even death. The symptoms of hypoglycaemia usually occur suddenly. They may include cold sweats, cool pale skin, fatigue, nervousness or tremor, anxiousness, unusual tiredness or weakness, confusion, difficulty in concentration, drowsiness, excessive hunger, vision changes, headache, nausea and palpitation.

In clinical trials, the frequency of hypoglycaemia varied with patient population, dose regimens and level of glycaemic control. During clinical trials the overall rates of hypoglycaemia did not differ between patients treated with insulin aspart compared to human insulin.

Skin and subcutaneous tissue disorders

Lipodystrophy (including lipohypertrophy, lipoatrophy) and cutaneous amyloidosis may occur at the injection site and delay local insulin absorption. Continuous rotation of the injection site within the given injection area may help to reduce or prevent these reactions (see section 4.4).

Paediatric population

Based on post-marketing sources and clinical trials with insulin aspart, the frequency, type and severity of adverse reactions observed in the paediatric population do not indicate any differences to the broader experience in the general population.

Other special populations

Based on post-marketing sources and clinical trials with insulin aspart, the frequency, type and severity of adverse reactions observed in the elderly patients and in patients with renal or hepatic impairment do not indicate any differences to the broader experience in the general population.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

A specific overdose for insulin cannot be defined, however, hypoglycaemia may develop over sequential stages if too high doses relative to the patient's requirement are administered:

• Mild hypoglycaemic episodes can be treated by oral administration of glucose or sugary products. It is therefore recommended that the diabetic patient always carries sugar‑containing products.

• Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated with glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously by a trained person, or with glucose given intravenously by physicians or other healthcare staff. Glucose must be given intravenously, if the patient does not respond to glucagon within 10 to 15 minutes. Upon regaining consciousness, administration of oral carbohydrates is recommended for the patient in order to prevent a relapse.

💬 Ask about this leaflet

Ask anything about Trurapi 100 units/ml solution for injection in pre-filled pen. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →